Find policies, billing codes, payers, states, and providers
HCPCS J3245: Injection, tildrakizumab, 1 mg
HCPCS Level II code J3245 designates a unit of the monoclonal antibody tildrakizumab (1 mg) used for subcutaneous biologic therapy. As a drug-specific HCPCS Level II code, J3245 is used on outpatient professional and facility claims to report the medication supplied for dosing and billing of biologic treatments. Nationally, accurate reporting of this code matters for drug spend tracking, utilization monitoring, and payer coverage decisions for specialty injectable therapies.
Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code and its clinical use, typical sites of service where the product is administered, and what is commonly reported alongside such HCPCS drug codes. The publication also outlines the types of benchmarks and policy topics typically relevant to this code, including reimbursement reporting, prior authorization considerations, and billing units for injectable biologics. Data not available in the input is noted where applicable.
This summary provides clinicians, billing professionals, and policy analysts a national-level reference for identification and clinical context of HCPCS Level II code J3245, and orients readers to the sections covering billing practice, payer coverage patterns, and coding considerations related to tildrakizumab injections.
Customize your policy alerts
Sign up for hcpcs J3245 policy alerts
Get alerted when payer policies referencing J3245 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J3245 represents Injection, tildrakizumab, 1 mg. This code denotes the supply unit for the biologic agent tildrakizumab intended for subcutaneous administration.
Service Type: Medication administration (biologic injectable)
Typical Site of Service: Outpatient infusion/infusion center, physician office, or clinic for subcutaneous biologic injection